Sonya Reid

10PUBLICATIONS
67CO-AUTHORS
Molecular targetsPredictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Aug 25, 2025
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

|Jul 15, 2024
Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort.

Xiaopeng Sun, Laura C Kennedy, Paula I Gonzalez-Ericsson

|Mar 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.

Erica L Mayer, Yue Ren, Nikhil Wagle

|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.

Kevin Kalinsky, Melissa K Accordino, Codruta Chiuzan

|Jun 24, 2022
Low-Salt Diet Reduces Anti-CTLA4 Mediated Systemic Immune-Related Adverse Events while Retaining Therapeutic Efficacy against Breast Cancer.

Durga Khandekar, Debolanle O Dahunsi, Isaac V Manzanera Esteve

Pageof 2

Frequent Collaborators

2 joint publications

Kathy Miller

2 joint publications

Sara M Tolaney

2 joint publications

Naomi Ko

2 joint publications

Yara Abdou